These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Marcucci G; Livak KJ; Bi W; Strout MP; Bloomfield CD; Caligiuri MA Leukemia; 1998 Sep; 12(9):1482-9. PubMed ID: 9737700 [TBL] [Abstract][Full Text] [Related]
5. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Jurlander J; Caligiuri MA; Ruutu T; Baer MR; Strout MP; Oberkircher AR; Hoffmann L; Ball ED; Frei-Lahr DA; Christiansen NP; Block AM; Knuutila S; Herzig GP; Bloomfield CD Blood; 1996 Sep; 88(6):2183-91. PubMed ID: 8822938 [TBL] [Abstract][Full Text] [Related]
6. Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia. Zhang L; Cao Z; Ruan M; Zeng Q; Zhao L; Li Q; Zou Y; Wang J; Zhu X Pediatr Blood Cancer; 2014 Oct; 61(10):1761-6. PubMed ID: 24920269 [TBL] [Abstract][Full Text] [Related]
7. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement. Martín G; Barragán E; Bolufer P; Chillón C; García-Sanz R; Gómez T; Brunet S; González M; Sanz MA Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121 [TBL] [Abstract][Full Text] [Related]
8. Use of the polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21). Kwong YL; Chan V; Wong KF; Chan TK Cancer; 1995 Feb; 75(3):821-5. PubMed ID: 7828132 [TBL] [Abstract][Full Text] [Related]
9. Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions. Laczika K; Mitterbauer G; Mitterbauer M; Knöbl P; Schwarzinger I; Greinix HT; Rabitsch W; Fonatsch C; Mannhalter C; Lechner K; Jaeger U Leuk Lymphoma; 2001; 42(5):923-31. PubMed ID: 11697647 [TBL] [Abstract][Full Text] [Related]
10. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K; Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435 [TBL] [Abstract][Full Text] [Related]
11. Monitoring of minimal residual leukemia in patients with MLL-AF9 positive acute myeloid leukemia by RT-PCR. Mitterbauer G; Zimmer C; Fonatsch C; Haas O; Thalhammer-Scherrer R; Schwarzinger I; Kalhs P; Jaeger U; Lechner K; Mannhalter C Leukemia; 1999 Oct; 13(10):1519-24. PubMed ID: 10516752 [TBL] [Abstract][Full Text] [Related]
12. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Kusec R; Laczika K; Knöbl P; Friedl J; Greinix H; Kahls P; Linkesch W; Schwarzinger I; Mitterbauer G; Purtscher B Leukemia; 1994 May; 8(5):735-9. PubMed ID: 7514242 [TBL] [Abstract][Full Text] [Related]
13. Molecular disease eradication is a prerequisite for long-term remission in patients with t(8;21) positive acute myeloid leukemia: a single center study. Mitterbauer M; Mitterbauer-Hohendanner G; Sperr WR; Kalhs P; Greinix HT; Fonatsch C; Haas OA; Jäger U; Mannhalter C; Lechner K Leuk Lymphoma; 2004 May; 45(5):971-7. PubMed ID: 15291357 [TBL] [Abstract][Full Text] [Related]
14. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Guerrasio A; Pilatrino C; De Micheli D; Cilloni D; Serra A; Gottardi E; Parziale A; Marmont F; Diverio D; Divona M; Lo Coco F; Saglio G Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450 [TBL] [Abstract][Full Text] [Related]
15. [Clinical significance of detection of AML1/ETO fusion transcripts in childhood AML using real-time quantitative reverse transcription polymerase chain reaction]. Liu CF; Liu GL; Zhang LP; Cheng YF; Lu AD; Tian KG; Liu YR; Qin YZ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):76-82. PubMed ID: 15748440 [TBL] [Abstract][Full Text] [Related]
17. [Detection of aml-1/eto fusion gene in patients with acute myeloid leukemia by real-time quantitative RT-PCR]. Jiang YM; Yuan H; Liu XY; Wang B; Li SJ; Wang N Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):17-22. PubMed ID: 19236739 [TBL] [Abstract][Full Text] [Related]
18. Disappearance of AML1-MTG8 transcript by reverse transcriptase polymerase chain reaction in a patient in remission of acute myeloid leukemia (M2) after low-dose cytosine arabinoside. Sawada H; Serino Y; Wake A; Yamasaki Y; Izumi Y Leuk Res; 1998 Sep; 22(9):853-7. PubMed ID: 9716019 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia. Cho EK; Bang SM; Ahn JY; Yoo SM; Park PW; Seo YH; Shin DB; Lee JH Korean J Intern Med; 2003 Mar; 18(1):13-20. PubMed ID: 12760263 [TBL] [Abstract][Full Text] [Related]
20. Diagnosis and follow-up of acute promyelocytic leukemia by detection of PML-RAR alpha gene rearrangement. Gau JP; Young JH; Lin TH; Yang YS Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar; 63(3):175-81. PubMed ID: 10746412 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]